Symbiotec Pharmalab IPO: Date, price, lot size, everything you need to know 

Symbiotec Pharmalab is a biopharmaceutical and biotechnology business that develops and manufactures active pharmaceutical ingredients, or APIs, and intermediates. The company has a strong presence in corticosteroids and steroidal hormone APIs, which are used in a range of pharmaceutical formulations. Its product portfolio also includes biotechnology-based ingredients, vitamins, minerals and nutraceutical ingredients for pharmaceutical, nutrition and wellness applications. 

Symbiotec Pharmalab is launching a ₹1,757 crore IPO, comprising a ₹150 crore fresh issue and a ₹1,607 crore Offer for Sale. The company will use ₹112.50 crore from the fresh issue for partial repayment or prepayment of borrowings and ₹37.50 crore for general corporate purposes. The OFS proceeds will go to the selling shareholders. 

Symbiotec Pharmalab IPO dates 

• IPO opening date: August 24, 2026
• IPO closing date: August 27, 2026
• Basis of allotment: August 28, 2026
• Refund initiation: August 31, 2026
• Demat credit: August 31, 2026
• Expected listing date: September 1, 2026 
• Book running lead managers: JM Financial, Avendus Capital Private, Motilal Oswal Investment Advisors, and Nomura Financial Advisory and Securities (India) 

Symbiotec Pharmalab IPO details 

The fresh issue will provide capital to Symbiotec Pharmalab for debt repayment and general corporate purposes. The Offer for Sale will allow existing shareholders, including Rosewood Investments and Motilal Oswal backed entities, to partially monetise their holdings. 

About Symbiotec Pharmalab 

Symbiotec Pharmalab operates in the specialised pharmaceutical ingredients segment. It manufactures steroid APIs and intermediates used by pharmaceutical formulators in therapeutic areas such as anti-inflammatory, dermatology, respiratory, hormonal and other treatments. 

The business combines chemical synthesis, fermentation and biotechnology capabilities, allowing it to cater to pharmaceutical and nutrition customers. Its product development, manufacturing process controls and compliance standards are central to its ability to serve regulated markets, where customers require reliable supply, consistent quality and product documentation. 

The company is based in Madhya Pradesh and supplies customers in India and overseas. Its growth will depend on demand for specialty APIs, new product launches, the ability to maintain regulatory compliance and progress in export markets. 

Symbiotec Pharmalab financials (₹ crore) 

Revenue from operations increased to ₹869.15 crore in FY26 from ₹751.55 crore in FY25 and ₹716.25 crore in FY24. Net profit increased to ₹109.90 crore in FY26 from ₹96.79 crore in FY25 and ₹100.06 crore in FY24, indicating improved profitability alongside revenue growth. EBITDA increased to ₹231.97 crore in FY26 from ₹206.11 crore in FY25, though the EBITDA margin moderated to 26.59% from 27.26%. 

Cash flow from operations improved to ₹174.60 crore in FY26 from ₹47.30 crore in FY25. Free cash flow remained negative at ₹49.81 crore in FY26, but the deficit narrowed substantially from negative ₹260.90 crore in FY25. The improvement reflects stronger operating cash generation, although capital expenditure of ₹237.31 crore continued to weigh on free cash flow. 

Sector and market context 

The pharmaceutical API industry benefits from demand for generic medicines, chronic therapies, healthcare access and the need for reliable manufacturing supply chains. India is an important global supplier of APIs and intermediates, supported by technical talent, manufacturing capability and a growing regulatory footprint. 

Steroid APIs are specialised products with meaningful technical and regulatory requirements. Demand can be supported by therapeutic applications across dermatology, respiratory care, inflammation and hormone treatments. However, API manufacturers face pressure from China based suppliers, customer concentration, regulatory inspections, raw material volatility, foreign exchange movements and changes in pharmaceutical demand. 

Key considerations for investors 

Strengths 

• Specialised presence in corticosteroid and steroidal hormone APIs, along with biotechnology and nutraceutical ingredients.
• Revenue from operations increased to ₹869.15 crore in FY26 from ₹751.55 crore in FY25 and ₹716.25 crore in FY24.
• Net profit increased to ₹109.90 crore in FY26 from ₹96.79 crore in FY25 and ₹100.06 crore in FY24.
• EBITDA increased to ₹231.97 crore in FY26 from ₹206.11 crore in FY25, indicating continued operating scale despite EBITDA margin moderating to 26.59% from 27.26%.
• Cash flow from operations improved to ₹174.60 crore in FY26 from ₹47.30 crore in FY25.
• Fresh issue proceeds include ₹112.50 crore for partial repayment or prepayment of borrowings, which can support the balance sheet.
• Demand potential across pharmaceutical, nutrition and wellness ingredient categories. 

Risks 

• Free cash flow remained negative at ₹49.81 crore in FY26, although the deficit narrowed from negative ₹260.90 crore in FY25.
• Capital expenditure of ₹237.31 crore in FY26 continued to weigh on free cash flow.
• EBITDA margin moderated to 26.59% in FY26 from 27.26% in FY25.
• The business depends on compliance with pharmaceutical manufacturing and product regulations in India and export markets.
• Competition from global and domestic API manufacturers can affect pricing, market share and margins.
• Raw material prices, foreign exchange movements and customer demand can affect profitability. 

Opportunities 

• Growing requirement for specialty APIs and intermediates in domestic and export pharmaceutical markets.
• Expansion in biotechnology and nutraceutical ingredients can diversify revenue streams.
• Debt reduction through the fresh issue can improve financial flexibility.
• Higher contribution from regulated markets and complex APIs may support long term growth, subject to product approvals and execution. 

Conclusion

Symbiotec Pharmalab offers exposure to the specialised pharmaceutical ingredients market, with presence in corticosteroid and steroidal hormone APIs. Revenue increased to ₹751.60 crore in FY25 from ₹566.50 crore in FY23, while the business remains exposed to regulatory, pricing and raw material risks. 

Investors should evaluate the significant OFS component, negative free cash flow of ₹49.81 crore in FY26, continued capital expenditure requirements, and the company’s ability to sustain quality and compliance standards while expanding across domestic and overseas markets.